Dr. Reddy's Laboratories Limited (RDY)
| Previous Close | 75.21 |
| Open | 74.89 |
| Bid | 0.00 x 800 |
| Ask | 75.47 x 1000 |
| Day's Range | 74.94 - 74.94 |
| 52 Week Range | 53.12 - 77.72 |
| Volume | |
| Avg. Volume | 186,368 |
| Market Cap | 12.633B |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | 19.98 |
| EPS (TTM) | 3.75 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | 0.49 (0.65%) |
| Ex-Dividend Date | Jul 07, 2023 |
| 1y Target Est | 79.86 |
Business WireDr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
Business WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
